1. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553-63.
  2. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009; 4:240-6.
  3. Parrish NF, Gao F, Li H et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013; 110:6626-33.
  4. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587-97.
  5. Loré K, Sönnerborg A, Broström C et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS 2002; 16:683-92.
  6. Granelli-Piperno A, Moser B, Pope M et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med 1996; 184:2433-8.
  7. Granelli-Piperno A, Delgado E, Finkel V et al. Immature dendritic cells selectively replicate macrophage tropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 1998; 72:2733-7.
  8. Zhu T, Wang N, Carr A et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-107.
  9. Mattapallil JJ, Douek DC, Hill B et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-7.
  10. Li Q, Duan L, Estes JD et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434:1148-52.
  11. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384:258-71.
  12. Seidlin M, Vogler M, Lee E, et al. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 1993; 7:1247-54.
  13. Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man’s infectiousness, and woman’s susceptibility. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1991; 151:2411-6.
  14. Vernazza PL, Gilliam BL, Dyer J et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11:987-93.
  15. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. medicine Eng J Med 2011; 365:493-505.
  16. Ronen K, Sharma A, Overbaugh J. HIV transmission biology: translation for HIV prevention. AIDS 2015; 29:2219-27.
  17. Martin HL Jr, Nyange PM, Richardson BA et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1053-9. 
  18. Winter AJ, Taylor S, Workman J et al. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999; 75:261-3.
  19. Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol 2015; 36:22-30.
  20. Sheffield JS, Wendel GD Jr, McIntire DD, Norgard MV. Effect of genital ulcer disease on HIV-1 coreceptor expression in the female genital tract. J Infect Dis 2007; 196:1509-16.
  21. Chakraborty H, Sen PK, Helms RW et al. Viral burden in genital secretions determines male- to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15:621-7.
  22. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-6.
  23. Freeman EE, Weiss HA, Glynn JR et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
  24. Kapiga SH, Sam NE, Bang H et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260-9.
  25. Zuckerman RA, Lucchetti  A,  Whittington  WL et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-8.
  26. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-9.
  27. Celum C, Wald A, Hughes J et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double blind, placebo-controlled trial. Lancet 2008; 371:2109-19.
  28. Kamali A, Quigley M, Nakiyingi J et al. Syndromic management of sexually- transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645-52.
  29. Sangani P, Rutherford G, Wilkinson D. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2004: CD001220.
  30. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-66.
  31. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-56.
  32. Tobian AA, Kacker S, Quinn TC. Male circumcision: a globally relevant but under-utilized method for the prevention of HIV and other sexually transmitted infections. Ann Rev Med 2014; 65:293-306.
  33. Altfeld M, Allen TM, Yu XG et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420:434-9.
  34. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192:438-44.
  35. Fang G, Weiser B, Kuiken C et al. Recombination following superinfection by HIV-1. AIDS 2004; 18:153-9.
  36. Blick G, Kagan RM, Coakley E et al. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 2007; 195:1250-9.
  37. Gonzales MJ, Delwart E, Rhee SY et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis 2003; 188:397-405.
  38. Manigart O, Courgnaud V, Sanou O et al. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS 2004; 18:1645-51.
  39. Smith DM, Wong JK, Hightower GK et al. Incidence of HIV superinfection following primary infection. JAMA 2004; 292:1177-8 
  40. Yerly S, Jost S, Monnat M et al.  HIV-1 co/super-infection in intravenous drug users. AIDS 2004; 18:1413-21.
  41. Redd AD, Quinn TC, Tobian AA. Frequency and implications of HIV superinfection. Lancet Infect Dis 2013; 13:622-8.
  42. Gottlieb G, Nickle D, Jensen M et al. HIV type 1 superinfection with a dual tropic virus and rapid progression to AIDS: a case report. Clin Infect Dis 2007; 45:501-9.
  43. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Petropoulos CJ, et al. HIV drug resistance acquired through superinfection. AIDS 2005; 19:1251-6.
  44. Casado C, Pernas M, Alvaro T, Sandonis V, Garcia S, Rodriguez C, et al. Co-infection and superinfection in patients with long-term, nonprogressive HIV-1 disease. J Infect Dis 2007; 196:895-9.
  45. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G,Karim SA, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004; 190:1355-9.
  46. Pernas M, Casado C, Fuentes R, et al. A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. J Acquir Immune Defic Syndr 2006; 42:12-8.
  47. Cavarelli M, Scarlatti G. HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection. J Transl Med. 2011; 9 Suppl 1:S10.
  48. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis 1997; 175:172-5.
  49. Cao Y, Krogstad P, Korber BT et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3:549-52.
  50. Ioannidis JP, Abrams EJ, Ammann A et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183:539-45.
  51. O'Donovan K, Emeto TI. Mother-to-child transmission of HIV in Australia and other high-income countries: Trends in perinatal exposure, demography and uptake of prevention strategies. Aust N Z J Obstet Gynaecol. 2018; 58:499-505.
  52. Maguire A, Sanchez E, Fortuny C, Casabona J.  Potential risk factors for vertical HIV-1 transmission in Catalonia, Spain: the protective role of cesarean section. The Working Group on HIV-1 Vertical Transmission in Catalonia. AIDS 1997; 11:1851-7.
  53. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340:585-8.
  54. Nduati R, John G, Mbori-Ngacha D,et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-74.
  55. Ratcliffe J, Ades AE, Gibb D, Sculpher MJ, Briggs AH. Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. AIDS 1998; 12:1381-8.
  56. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 1999; 354:471-6.
  57. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000; 14:2535-41.
  58. John GC, Rousseau C, Dong T, et al. Maternal SDF1 3’A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000; 74:5736-9.
  59. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc. 1998; 129:851-8.
  60. Gilbart VL, Evans BG, Dougan S. HIV transmission among men who have sex with men through oral sex. Sex Transm Infect. 2004; 80:324.
  61. Page-Shafer K, Shiboski CH, Osmond DH, et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS. 2002; 16:2350-2.
  62. Ruprecht RM, Baba TW, Liska V, et al. Oral transmission of primate lentiviruses. J Infect Dis 1999; 179 Suppl 3: S408-S412.
  63. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-62.
  64. Koup RA, Safrit JT, CaoY, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
  65. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988; 148:945-9.
  66. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154-7.
  67. Pedersen C, Katzenstein T, Nielsen C et al. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:93-9.
  68. Boufassa F, Bachmeyer C, Carré N, et al. Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis 1995; 171:1190-5. 
  69. Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness:  a dose-response relationship. Clin Infect Dis 1998; 26:323-9.
  70. Goujard C, Bonarek M, Meyer L, et al. CD4 Cell Count and HIV DNA Level Are Independent Predictors of Disease Progression after Primary HIV Type 1 Infection in Untreated Patients. Clin Infect Dis 2006; 42:709-15.
  71. Blattner WA, Oursler KA, Cleghorn F, et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004; 189:1793-801.
  72. Lavreys L, Baeten JM, Overbaugh J, et al. Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis 2002; 35:77-81.
  73. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
  74. Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990; 301:1183-8.
  75. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
  76. Demarest JF, Jack N, Cleghorn FR, et al. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 2001; 17:1333-44.
  77. Strathdee SA, Craib KJ, Hogg RS, et al. Long-term non-progression in HIV infection. Lancet 1995; 346:1372.
  78. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV Natural History Study. J Infect Dis 2009; 200:1714–1723.
  79. Lambotte O, Boufassa F, Madec Y, et al. HIV Controllers: A Homogeneous Group of HIV-1 Infected Patients with Spontaneous Control of Viral Replication. Clin Infect Dis 2005; 41:1053-6.
  80. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-71.

  1. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
  2. Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA1987; 257:331-4.
  3. Eyster ME, Ballard JO, Gail MH, et al. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. Ann Intern Med 1989; 110:963-9.
  4. Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5:365-72.
  5. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337:389-92.
  6. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-5.
  7. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80.
  8. van Asten L, Danisman F, Otto SA, et al. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS 2004; 18:1885-93.
  9. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-55.
  10. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59.
  11. Katzenstein TL, Pedersen C, Nielsen C, et al. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10:167-73.
  12. Bruisten SM, Frissen PH, Van Swieten P, et al. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons. AIDS Res Hum Retroviruses 1997; 13:327-35.
  13. Hecht FM, Hartogensis W, Bragg L, et al. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 2010; 24:941-5.
  14. Sabin CA, Lundgren JD. The natural history of HIV infection. Current Opinion in HIV and AIDS 2013; 8:311-7.
  15. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46-55.
  16. Helleberg M, Kronborg G, Larsen CS, et al. No change in viral set point or CD4 cell decline among antiretroviral treatment-naive, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010. HIV Medicine 2013; 14:362-9.
  17. Giorgi JV, Ho HN, Hirji K, et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 1994; 170:775-81.
  18. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10:827-34.
  19. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70.
  20. McLaren PJ, Carrington M. The impact of host genetic variation on infection with HIV-1. Nature Immunology 2015; 16:577-83.
  21. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
  22. Biti R, Ffrench R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3:252-3.
  23. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4:350-3.
  24. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-40.
  25. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7.
  26. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-91.
  27. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-4.
  28. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510-4.
  29. Sterling TR, Lyles CM, Vlahov D, et al. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-672.
  30. Moore RD, Cheever L, Keruly JC, Chaisson RE. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 1999; 353:463-4.
  31. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ 1994; 309:1537-42.
  32. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270:988-91.
  33. Daar E, Kesler K, Petropoulos C, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9.
  34. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
  35. de Brito A, Komninakis SC, Novoa P, et al. Women infected with HIV type 1 Brazilian variant, subtype B (B’-GWGR motif) have slower progression to AIDS, compared with patients infected with subtype B (B- GPGR motif). Clin Infect Dis 2006; 43:1476-81.
  36. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-52.
  37. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-80.
  38. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-13.
  39. John-Stewart GC, Nduati RW, Rousseau CM, et al. Subtype C Is associated with increased vaginal shedding of HIV-1. J Infect Dis 2005; 192:492-6.
  40. Barbour JD, Hecht FM, Wrin T, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251-6.
  41. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715-24.
  42. Xiang J, Wünschmann S, Diekema DJ, et al. Effect of co-infection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707-14.
  43. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in co-infected persons. J Infect Dis 1999; 179:783-9.
  44. Yeo AE, Matsumoto A, Hisada M, et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959-63.
  45. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336:747-54.
  46. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997; 336:741-6.
  47. Schwarze-Zander C, Blackard JT, Rockstroh JK. Role of GB virus C in modulating HIV disease. Expert Review of Anti-infective Therapy 2012; 10:563-72.
  48. Xiang J, George SL, Wunschmann S, et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040-6.
  49. Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350:981-90.